Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

52 week Range -
/

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change

2 Cannabis Stocks Set to Double in 2021

2 Cannabis Stocks Set to Double in 2021 The cannabis industry has gained plenty of momentum over the last couple of months. Folks in 36 states now have access to medical cannabis and federal decriminalization seems more imminent now than ever. It may be time for...

What are the Top 3 Cannabis Beverage Stocks for 2021?

What are the Top 3 Cannabis Beverage Stocks for 2021? The CBD infused beverages market is exploding. In fact, this emerging market will have a value of nearly $3 Billion in the next 4 years. Many cannabis and hemp companies are cashing in on the opportunity, allowing...

Should You Buy Curleaf Stock Before the Q4 Earnings Call?

Should You Buy Curleaf Stock Before the Q4 Earnings Call? Cannabis legalization in various US states are proving to be an absolute game-changer in the market. Multiple cannabis stocks have gained momentum, and a few companies surprised investors with their expansion...

Sundial Growers: Should You Buy this Cannabis Stock?

Sundial Growers: Should You Buy this Cannabis Stock? Canada is one of the largest hubs for the cannabis industry. It has also become one of the largest producers of cannabidiol (CBD), and other cannabis-based medications. As with any emerging industry, we tend to see...

Top 3 Cannabis ETFs to Watch in 2021

Top 3 Cannabis ETFs to Watch in 2021 Legal cannabis has been slowly growing in the United States since the campaign to legalize marijuana for medical and recreational purposes. In 2018, the cannabis industry was valued at $12 billion US dollars. It is now expected to...

Trulieve: Top Cannabis Stock for 2021

Trulieve: Top Cannabis Stock for 2021 The global cannabis industry is set to quadruple in the next six years from a $20 billion industry to a $90 billion one. Post Biden’s win, the industry has found a new reason to cheer.  The new administration's pro-pot stance will...

Top 5 Most Lucrative Industrial Hemp Products

Top 5 Most Lucrative Industrial Hemp Products As cannabis use becomes more mainstream, both for medical and recreational use, more people are looking to invest in the cannabis industry. Many of them choose to enter as retail investors or as business owners starting...

What does the SAFE Banking Act Mean for the Cannabis Industry?

What does the SAFE Banking Act Mean for the Cannabis Industry? One of the main changes on the horizon that many in the cannabis industry are eagerly anticipating is the passing into federal law of the SAFE Banking Act, which seems more likely now that it made it...

Thinking about Investing in Cannabis ETFs?

Thinking about Investing in Cannabis ETFs? Cannabis stocks continue to rise since the November election in the United States as more states voted to legalize recreational consumption of cannabis. That vote, and the hope that the federal government is finally going to...

Is AYR Wellness the Marijuana Stock You’ve Been Waiting For?

Is AYR Wellness the Marijuana Stock You've Been Waiting For? The marijuana industry continues to remain a hot sector in 2021, and the recent US elections gave a further boost to the industry when the dialogue began about decriminalizing marijuana at the federal level....